Abnormal expression and mutation of p53 in cervical cancer - A study at protein, RNA and DNA levels

Sexually Transmitted Infections

Volumn 73, Issue 1, 1997, Pages 54-58

  Ngan, Hextan Y S ^a   Tsao, Sai Wak ^a   Liu, Stephanie S ^a   Stanley, Margaret ^b  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Cervical cancer; HPV; Mutation; p53; RNA

Indexed keywords

EID: 79960451862     PISSN: 13684973     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/sti.73.1.54     Document Type: Article

References (26)

1. Zur Hausen H. Human papillomaviruses in the pathogenesis of anogenital cancer. Virology 1991;184:9-13.
2. IARC. IARC Monographs on the evaluation of carcinogenic risks to humans. In: Human Papillomavirus Lyon, France: IARC, 1995;64:130-84.
3. Wright TC, Richart RM. Role of human papillomavirus in the pathogenesis of genital tract warts and cancer. Gynocol Oncol 1990;37:151-64. (Pubitemid 20182275)
4. Werness BA, Levine AJ, Howley PM. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 1990;248:76-9.
5. Crook T, Wrede D, Vousden KH. p53 point mutation in HPV negative human cervical carcinoma cell lines. Oncogene 1991;6:873-5. (Pubitemid 21924163)
6. Crook T, Wrede D, Tidy JA, Mason WP, Evans DJ, Vousden KH. Clonal p53 mutation in primary cervical cancer: association with human-papillomavirus- negative tumours. Lancet 1992;339:1070-3.
7. Fujita M, Inoue M, Tanizawa O, Iwamoto S, Enomoto T. Alterations of the p53 gene in human primary cervical carcinoma with and without human papillomavirus infection. Cancer Res 1992;52:5323-8.
8. Kessis TD, Slebos RJ, Han SM, Shah K, Bosch XF, Munoz N, et al. p53 gene mutations and MDM2 amplification are uncommon in primary carcinoma of the uterine cervix. Am J Pathol 1993;143:1398-405. (Pubitemid 24057110)
9. Miwa K, Miyamoto S, Kato H, et al. The role of p53 inactivation in human cervical cell carcinoma development. Br J Cancer 1995;71:219-26.
10. Ngan HYS, Stanley M, Liu SS, Ma HK. HPV and p53 in cervical cancer. Genitourin Med 1995;70:167-70. (Pubitemid 24220319)
11. Chomcznski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocynate-phenol-chloroform extraction. Anal Biochem 1987;162:156-9. (Pubitemid 17064313)
12. Hsu LC, Metcalf T, Sun T, Welsh NJ, Wang NJ, Harris CC. Mutational hotspot in the p53 gene in human hepatocellular carcinoma. Nature 1991;350:427-8. (Pubitemid 21912245)
13. Okamoto A, Sameshima Y, Yokoyama S, Shinsky JJ, White TJ. Frequent allelic losses and mutations of the p53 gene in human ovarian cancer. Cancer Res 1991;51:5171-6.
14. Mok SCH, Lo KW, Tsao SW. Direct cycle sequencing of mutated alleles detected by PCR single-strand conformation polymorphism analysis. Biofeedback 1993;14:790-3.
15. Ting Y, Manos MM. A guide to methods and applications. In: Gelfand DH, et al, eds. PCR Protocols. CA: Academic Press Inc, 1990:356-67.
16. Collins RJ, Ngan HYS, Hsu C, Cheung A, King P, Pun TC, et al. Human papillomavirus infection in the cervix of pregnant females in Hong Kong. Cytopathology 1990;1:147-52.
17. Ngan HYS, Collins RJ, Wong KY, Cheung A, Lai CF, Liu YT. Cervical human papillomavirus infection in women attending social hygiene clinics in Hong Kong. Int J Gynaecol Obstet 1993;41:75-9. (Pubitemid 23115538)
18. Cooper K, Herrington CS, Evans MF, Gatter KC, McGee JO. p53 antigen in cervical condyloma, intraepithelial neoplasia, and carcinoma: relationship to HPV infection and integration. J Pathol 1993;171:27-34.
19. Jacquemier J, Moles JP, Penault-Llorca F, et al. p53 immunohistochemical analysis is breast cancer with four monoclonal antibodies: comparison of staining and PCRSSCP results. Br J Cancer 1994;69:846-52. (Pubitemid 24140662)
20. Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW, Vogelstein B. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 1993;362:857-60. (Pubitemid 23132165)
21. Kastan MB, Zhan Q, el Deiry WS, Carrier F, Jacks T, Walsh W, et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxiatelangiectasia. Cell 1992;71:587-97.
22. Midgley CA, Fisher CJ, Bartek J, Vojtesek B, Lane D, Barnes DM. Analysis of p53 expression in human tumours: an antibody raised against human p53 expressed in Escherichia coli. J Cell Science 1992;101:183-9.
23. Lee JH, Kang YS, Koh JW, Park SY, Kim BG, Lee ED, et al. p53 gene mutation is rare in human cervical carcinomas with positive HPV sequences. Int J Gynecol Cancer 1994;4:371-8.
24. Busby-Earle RMC, Steel CM, Williams ARW, Cohen B, Bird CC. p53 mutations in cervical carcinogenesis - low frequency and lack of correlation with human papillomavirus status. Br J Cancer 1994;69:732-7. (Pubitemid 24112696)
25. Helland A, Holm R, Kristensen G, Kaem J, Karlsen F, Tope C, et al. Genetic alterations of the TP53 gene, p53 protein expression and HPV infection in primary cervical carcinomas. J Pathol 1993;171:105-14. (Pubitemid 23309731)
26. Park DJ, Wilczymski SP, Paquette RL, Miller CW, Koeffler HP. p53 mutations in HPV-negative cervical carcinoma. Oncogene 1994;9:205-10.